Zacks Research Issues Pessimistic Forecast for MMSI Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Equities research analysts at Zacks Research cut their FY2025 EPS estimates for Merit Medical Systems in a note issued to investors on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings of $3.67 per share for the year, down from their prior estimate of $3.70. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share.

A number of other brokerages have also recently weighed in on MMSI. Wells Fargo & Company reduced their price target on shares of Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Raymond James lifted their price target on shares of Merit Medical Systems from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Tuesday, December 31st. Needham & Company LLC reduced their price target on shares of Merit Medical Systems from $122.00 to $116.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and set a $116.00 price target (up from $114.00) on shares of Merit Medical Systems in a research report on Wednesday, January 29th. Finally, Canaccord Genuity Group reduced their target price on shares of Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.78.

Merit Medical Systems Trading Up 0.4 %

Shares of MMSI stock opened at $101.68 on Friday. The stock has a market cap of $5.98 billion, a price-to-earnings ratio of 49.84, a price-to-earnings-growth ratio of 2.34 and a beta of 0.91. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. Merit Medical Systems has a fifty-two week low of $70.70 and a fifty-two week high of $111.45. The firm’s 50 day moving average price is $103.93 and its two-hundred day moving average price is $100.78.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MMSI. Vanguard Group Inc. lifted its position in shares of Merit Medical Systems by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 6,648,659 shares of the medical instruments supplier’s stock worth $643,058,000 after buying an additional 63,314 shares during the last quarter. State Street Corp lifted its position in shares of Merit Medical Systems by 0.7% in the 3rd quarter. State Street Corp now owns 2,231,701 shares of the medical instruments supplier’s stock worth $220,559,000 after buying an additional 15,098 shares during the last quarter. FMR LLC lifted its position in shares of Merit Medical Systems by 31.6% in the 4th quarter. FMR LLC now owns 2,076,439 shares of the medical instruments supplier’s stock worth $200,833,000 after buying an additional 499,193 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its position in shares of Merit Medical Systems by 2.3% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,633,246 shares of the medical instruments supplier’s stock worth $157,968,000 after buying an additional 36,489 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of Merit Medical Systems by 8.3% in the 4th quarter. Invesco Ltd. now owns 1,535,468 shares of the medical instruments supplier’s stock worth $148,510,000 after buying an additional 118,142 shares during the last quarter. 99.66% of the stock is currently owned by institutional investors.

Insider Activity at Merit Medical Systems

In other Merit Medical Systems news, Director Stephen C. Evans sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $105.31, for a total transaction of $526,550.00. Following the transaction, the director now directly owns 4,657 shares in the company, valued at $490,428.67. This represents a 51.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Raul Jr. Parra sold 12,451 shares of the stock in a transaction on Friday, February 28th. The shares were sold at an average price of $98.81, for a total transaction of $1,230,283.31. Following the transaction, the chief financial officer now owns 24,201 shares in the company, valued at $2,391,300.81. This trade represents a 33.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 109,132 shares of company stock valued at $11,139,521 over the last ninety days. Corporate insiders own 3.70% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.